(NASDAQ: VIR) Vir Biotechnology's forecast annual revenue growth rate of 49.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.85%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Vir Biotechnology's revenue in 2025 is $20,861,000.On average, 3 Wall Street analysts forecast VIR's revenue for 2025 to be $3,948,906,794, with the lowest VIR revenue forecast at $414,714,009, and the highest VIR revenue forecast at $9,400,184,204. On average, 3 Wall Street analysts forecast VIR's revenue for 2026 to be $3,414,478,674, with the lowest VIR revenue forecast at $414,714,009, and the highest VIR revenue forecast at $7,326,614,159.
In 2027, VIR is forecast to generate $11,038,304,540 in revenue, with the lowest revenue forecast at $5,280,691,715 and the highest revenue forecast at $21,316,300,063.